Insights
Search Results
Client Highlights
6.16.26
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Client Highlights
6.10.26
Wilson Sonsini Advises Kiavi on $717 Million Acquisition by Figure
On June 10, 2026, Figure Technology Solutions (Figure), the blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, announced a definitive agreement to acquire Kiavi, an AI-powered lending platform for residential real estate investors. The transaction includes the purchase of Kiavi’s balance sheet assets by a joint venture between Figure and Sixth Street, a leading global investment firm, who is buying loans off Kiavi’s balance sheet. The total transaction purchase price is $717 million. Wilson Sonsini Goodrich & Rosati is advising Kiavi on the transaction.
Client Highlights
6.05.26
Wilson Sonsini Advises SewerAI on Strategic Investment
On June 2, 2026, SewerAI, a leading AI platform for sewer and underground infrastructure intelligence, announced a major strategic investment led by JMI Equity, a leading growth equity software investor based in the greater Washington, D.C., area and San Diego, with continued participation from Innovius Capital, Epic Ventures, and Bentley Systems. Wilson Sonsini Goodrich & Rosati advised SewerAI on the transaction.
Client Highlights
6.04.26
Wilson Sonsini Advises Cloudflare on Acquisition of VoidZero
On June 4, 2026, Cloudflare, a leading connectivity cloud company, announced it has acquired VoidZero, an open source-first company behind the next-generation JavaScript tooling ecosystem Vite. The acquisition will unify VoidZero’s high-performance tooling including the Vite build tool, Vitest test runner, Rust-based Rolldown bundler, and Oxc toolchain natively into the Cloudflare ecosystem. Wilson Sonsini Goodrich & Rosati advised Cloudflare on the transaction.
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
4.08.26
Wilson Sonsini Advises Sportsbox on Acquisition by Investor Group Led by Bryson DeChambeau
On April 7, 2026, a group of investors led by professional golfer Bryson DeChambeau announced its acquisition of Sportsbox AI, a leader in kinematic AI technology and 3D motion capture for coaching and training across mobile sports and fitness applications. Wilson Sonsini Goodrich & Rosati advised Sportsbox on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
1.07.26
Wilson Sonsini Advises OneStream on Acquisition by Hg
On January 6, 2026, OneStream, the leading enterprise finance management platform, announced that it has entered into a definitive agreement to be acquired by Hg, a leading investor in software, services, and data businesses. The all-cash transaction values OneStream at approximately $6.4 billion in equity value. Wilson Sonsini Goodrich & Rosati advised OneStream on this transaction in a continuation of its long-standing advisory relationship with the company, including leading OneStream’s Up-C IPO in July 2024.